Budz Is Protesting Again
This Time It’s Federal Cannabis Policy.
He’s outside protesting again. Beads swinging. Headband tight. Sign in the air.
“END THE WAR.”
And honestly? He’s not wrong.
Because of this Schedule III move, everyone’s celebrating?
It’s not a full win. It’s a selective one.
Medical cannabis just got:
- Federal legitimacy
- Tax relief runway
- A cleaner story for investors
Recreational?
Still stuck in the same gray-zone hustle.
Still profitable. Still growing. Still… not fully recognized.
And that split matters more than people think.
Follow the money (because Budz always does)
Cannabis operators finally get a little breathing room.
But pharma?
They just got invited to the table.
Cleaner research pathways.
FDA alignment.
Future insurance-backed revenue.
That’s not competition.
That’s a parallel system with better lighting and fewer questions.
Meanwhile, in your portfolio…
Cannabis stocks have been running on “almost” for years.
- Almost legal.
Almost normalized.
Almost investable.
And “almost” doesn’t pay.
So yeah… maybe this shift helps.
Maybe capital starts creeping back in.
Maybe companies like Canopy get their long-awaited U.S. angle sharpened.
But don’t miss what’s happening at the same time:
Pharma isn’t waiting.
They’re building.
The uncomfortable truth
This isn’t about cannabis winning or losing.
It’s about who gets to win cleanly.
Right now?
That answer depends on which side of the counter you’re standing on.
Or whether you’re wearing a lab coat.
Budz is still outside, by the way.
Different decade. Same protest.